The effect of food on the absorption and pharmacokinetics of rivaroxaban

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 7, 2013, Pages 549-561

  Stampfuss, Jan ^a   Kubitza, Dagmar ^a   Becka, Michael ^a   Mueck, Wolfgang ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Anticoagulation; Bioavailability; Food effect; Rivaroxaban

Indexed keywords

RIVAROXABAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SOLUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EPISTAXIS; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; GASTROINTESTINAL DISEASE; HEMATOMA; HERPES LABIALIS; HUMAN; HUMAN EXPERIMENT; INJECTION SITE HEMATOMA; INJECTION SITE REACTION; KNEE PAIN; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL STIFFNESS; NECK PAIN; NORMAL HUMAN; OPEN STUDY; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RHINITIS; RHINOPHARYNGITIS; SINGLE DRUG DOSE; STEADY STATE; SUBCUTANEOUS HEMATOMA; SUSPENSION; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VESSEL PUNCTURE SITE REACTION;

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MORPHOLINES; POSTPRANDIAL PERIOD; THIOPHENES; YOUNG ADULT;

EID: 84880237573     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201812     Document Type: Article

References (25)

1. Weitz JI. New oral anticoagulants in development. Thromb Haemost. 2010; 103: 62-70. CrossRef PubMed
2. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P. Dose-escalation study of rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor- for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res. 2007; 120: 685-693. CrossRef PubMed (Pubitemid 47268049)
3. Turpie AGG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M; ODIXa-Knee Study Group. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005; 3: 2479-2486. Cross- Ref PubMed (Pubitemid 41727165)
4. Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kälebo P; ODIXa- HIP Study Investigators. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006; 4: 121-128. CrossRef PubMed
5. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S; ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007; 116: 180-187. CrossRef PubMed (Pubitemid 47057524)
6. Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A; Einstein-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008; 112: 2242-2247. CrossRef PubMed
7. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM; ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009; 374: 29-38. CrossRef PubMed
8. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358: 2765-2775. CrossRef PubMed (Pubitemid 351930851)
9. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372: 31-39. CrossRef PubMed
10. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358: 2776-2786. CrossRef PubMed (Pubitemid 351930852)
11. Turpie AGG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373: 1673-1680. CrossRef PubMed
12. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363: 2499-2510. CrossRef PubMed
13. Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A; EINSTEIN- PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366: 1287-1297. CrossRef PubMed
14. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891. CrossRef PubMed
15. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook- Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9-19. Cross- Ref PubMed
16. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011; 10: 61-75. CrossRef PubMed
17. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006; 46: 549-558. CrossRef PubMed
18. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005; 3: 514-521. CrossRef PubMed (Pubitemid 41632877)
19. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005; 61: 873-880. CrossRef PubMed (Pubitemid 41803696)
20. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005; 78: 412-421. CrossRef PubMed (Pubitemid 41393676)
21. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry: food-effect bioavailability and fed bioequivalence studies. 2002. Available at: http://www.fda. gov/downloads/regulatoryinformation/guidances/ucm126833.pdf [accessed 26 October 2012].
22. Rohde G. Determination of rivaroxaban-a novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 872: 43-50. CrossRef PubMed
23. Turpie AGG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost. 2011; 105: 444-453. CrossRef PubMed
24. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2000. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformat ion/Guidances /ucm070246.pdf [accessed 25 October 2012].
25. Bayer Pharma AG. Xarelto® (rivaroxaban) Summary of Product Characteristics. 2012. Available at: http://www.xarelto.com/html/downloads/ Xarelto-Prescribing-Information-May-2012.pdf [accessed 18 October 2012]. Development, LLC